Karam Elias Antoine, Céline Yaghi César, Prince Gilles, Attieh Fouad, Kourie Hampig Raphael, Kattan Joseph, Nemer Elie
Departements de Médecine Oncologique, Gustave Roussy F-94805, Villejuif, France.
Department of Hematology-Oncology, Faculty of Medicine, Saint-Joseph University of Beirut, Lebanon.
Oncotarget. 2025 Jun 17;16:481-494. doi: 10.18632/oncotarget.28741.
Often associated with a poor prognosis, advanced urothelial carcinoma (aUC) has progressed to muscle-invasive or metastatic stages. Traditionally, chemotherapy has been the primary treatment for aUC, though its effectiveness in advanced stages remains limited. Recent developments have introduced promising therapies, notably the combination of enfortumab vedotin with pembrolizumab, which is now recommended as the first-line therapy following the EV-302 trial results. This combination has demonstrated significant improvements in survival rates. This review aims to explore the evolution of treatment strategies for aUC, emphasizing the shift towards immunotherapy and targeted therapies, and discusses the potential for optimized treatment algorithms to improve patient outcomes.
晚期尿路上皮癌（aUC）通常预后较差，已进展至肌肉浸润或转移阶段。传统上，化疗一直是aUC的主要治疗方法，但其在晚期的有效性仍然有限。最近的进展带来了有前景的疗法，特别是恩杂鲁胺与帕博利珠单抗的联合疗法，根据EV - 302试验结果，该联合疗法现已被推荐为一线治疗方案。这种联合疗法已证明在生存率方面有显著提高。本综述旨在探讨aUC治疗策略的演变，强调向免疫疗法和靶向疗法的转变，并讨论优化治疗方案以改善患者预后的潜力。
